Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management
Open accessThe DOI matches its Crossref record; 129 of the 130 references it cites were found in a registry or an index; 83 of the 116 sources its claims cite were checked for support.
Abstract
The 'Body Mass Index' (BMI) is an anachronistic and outdated ratio that is used as an internationally accepted diagnostic criterion for obesity, and to prioritise, stratify, and outcome-assess its management options. On an individual level, the BMI has the potential to mislead, including inaccuracies in cardiovascular risk assessment. Furthermore, the BMI places excessive emphasis on a reduction in overall body weight (rather than optimised body composition) and contributes towards a misunderstanding of the quiddity of obesity and a dispassionate societal perspective and response to the global obesity problem. The overall objective of this review is to provide an overview of obesity that transitions away from the BMI and towards a novel vista: viewing obesity from the perspective of the skeletal muscle (SM). We resurrect the SM as a tissue hidden in plain sight and provide an overview of the key role that the SM plays in influencing metabolic health and efficiency. We discuss the complex interlinks between the SM and the adipose tissue (AT) through key myokines and adipokines, and argue that rather than two separate tissues, the SM and AT should be considered as a single entity: the 'Adipo-Muscle Axis'. We discuss the vicious circle of sarcopenic obesity, in which aging- and obesity-related decline in SM mass contributes to a worsened metabolic status and insulin resistance, which in turn further compounds SM mass and function. We provide an overview of the approaches that can mitigate against the decline in SM mass in the context of negative energy balance, including the optimisation of dietary protein intake and resistance physical exercises, and of novel molecules in development that target the SM, which will play an important role in the future management of obesity. Finally, we argue that the Adipo-Muscle Ratio (AMR) would provide a more clinically meaningful descriptor and definition of obesity than the BMI and would help to shift our focus regarding its effective management away from merely inducing weight loss and towards optimising the AMR with proper attention to the maintenance and augmentation of SM mass and function.
Overview
CoChat Summary
## TL;DR
This narrative review argues that skeletal muscle mass and function should be central to obesity management, not just body weight or BMI. The authors propose the Adipo–Muscle Ratio (AMR) as a more clinically meaningful obesity descriptor than BMI because it would capture both adipose tissue and skeletal muscle.
## Key findings
- Skeletal muscle is presented as a major determinant of metabolic health: it accounts for >80% of post-prandial glucose uptake and is described as the largest thermogenic organ and a key contributor to basal metabolic rate.
- Age-related decline in skeletal muscle mass was reported to start in the third decade and become noticeable beyond age 50; sarcopenic obesity is said to affect around 11% of older adults globally, with prevalence increasing beyond age 70.
- During sustained negative energy balance, the review states that ~25% of total body weight loss typically comes from fat-free mass, and in a review of GLP1-based therapies, fat-free mass loss was reported as 20–40% of total body weight loss, with most studies >25%.
- In a human randomized placebo-controlled trial of bimagrumab in adults with T2D and overweight/obesity over 48 weeks, the treatment group had 20.5% fat mass reduction, 3.6% lean mass increase, 9 cm waist circumference reduction, and 0.76% HbA1c reduction.
## Methods
- The paper is a narrative review of current literature, using PubMed.
- Search terms included “obesity,” “metabolism,” and “skeletal muscle”; the authors included peer-reviewed articles of many types, with no publication-date restrictions and English-language only.
- Study selection was based on the authors’ perceived clinical relevance, novelty, and relative size; the paper does not report a formal systematic search or meta-analysis.
## Limitations
- The paper states it is a narrative review, and it explicitly says the field is “vast and goes beyond the scope of this concise review.”
- The selection process was based on authors’ judgment rather than a predefined systematic or exhaustive protocol, which limits reproducibility and makes selection bias evident from the text.
- The paper is largely conceptual and argumentative; where it cites studies, it does not conduct a new empirical analysis, so many claims depend on previously published work rather than original data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
66 Valid · 2 Not valid · 16 Not checked · 37 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“There is a close physical proximity and interplay between the SM and AT regarding their anatomy and physiology, a scenario that is ripe for bidirectional paracrine effects.”
§ Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management > 1. Introduction The global prevalence of obesity now exceeds 890 million, with overweight affecting around 2.5 billion adults [1]. The World Health Organisation (WHO) classifies obesity as a non-infectious global pandemic [1]. This positioning of obesity as a worldwide public health problem promotes renewed and redoubled efforts to develop and implement effective preventive, diagnostic, and management strategies. Obesity confers a substantial burden upon humanity, with impairments in quality of life and wellbeing that stem from its association with wide-reaching negative sequelae including impairments in psychosocial functioning [2] and work productivity [3]. Furthermore, obesity contributes towards a major component of global healthcare expenditure [4], originating from both the direct costs of obesity management, and the indirect costs associated with >50 obesity-related co-morbidities. Indeed, many chronic diseases that manifest within the modern-day clinical arena stem directly from weight gain and obesity or are at least pathophysiologically vulnerable to the metabolic and/or physical ramifications of obesity. Within this context, Type 2 Diabetes Mellitus (T2D) is notable, including a plethora of other obesity-related metabolic dysfunctional conditions such as dyslipidaemia, dysglycaemia, hypertension, Obstructive Sleep Apnoea (OSA), Polycystic Ovary Syndrome (PCOS), and Metabolic-Associated Fatty Liver Disease (MAFLD) [5]. Furthermore, obesity is associated with multiple malignancies that in turn contribute towards premature mortality [6,7]. Insulin resistance (IR, often associated with oxidative stress and chronic inflammatory status) is a key mediator between obesity and its adverse metabolic sequelae, and develops in the context of excessive adiposity, particularly visceral adiposity and ectopic fat deposition (epicardial, hepatic, and intramyocellular lipid [IMCL]) [8]. Obesity is a heterogeneous clinical entity with distinct subtypes based on underlying genetic architecture and clinical phenotypic biomarkers that include measures of insulin sensitivity, glycaemia, physical fitness, body composition, and cardiovascular risk [9]. One key challenge for the field of obesity is the relative lack of refinement concerning its definition. This has compounded societal misunderstanding of obesity and perhaps has also contributed towards a widespread stigmatisation and dispassionate perspective of obesity [10]. Such lack of diagnostic refinement has also stymied the development and implementation of more effective and targeted management guidelines for obesity from esteemed societies and has resulted in an unfortunate over-emphasis on ‘percentage body weight loss’ as a key outcome variable for both the clinical management of obesity and the assessment of novel therapies for obesity. The concept of ‘body weight divided by height squared’ as an indicator of body size was originally proposed by Quetelet and was widely adopted as the ‘Body Mass Index’ in the 1980s [11,12]. Since then, our definition of obesity has rested firmly on the BMI. To account for differences in overall cardiovascular risk between ethnic-specific groups based on the BMI, NICE provide ethnic-specific cut-offs for the BMI to define obesity. However, population-based data from a cohort in England demonstrate marked ethnic-specific variance in the risk of developing T2D based on the BMI [13]. To validate and confirm these insights, there is a requirement for further similar population-based studies on cohorts from different geographical locations and with controls for potential confounders such as socio-economic groups. Most guidelines on obesity management from esteemed societies refer solely to the BMI [14]. There are various problems with the BMI as a key solitary definition of obesity (and by implication nutritional status), not the least of which being that the BMI fails as a meaningful clinical entity at extremes of body habitus (in which there is either excessive or severely diminished muscularity) [12]. Furthermore, the BMI provides no indication of overall adiposity or body fat distribution (including the amount of visceral or ectopic fat). At one extreme, there are people with excessive muscularity (such as body builders) with lean mass exceeding 70% in some cases, in whom the BMI is elevated accordingly. Such a clinical scenario creates potential for confusion and mismanagement based on the imaginatively impoverished and unidimensional, but internationally accepted, BMI criteria for defining obesity and stratifying and prioritising its management approach. Whilst some readers may think that using the example of a body builder is meaningless as the absence of excessive adiposity is obvious clinically, there are plenty of other examples that are relatively common within the clinical arena where accurate assessment of the musculature is challenging, in which cases the application of the BMI can genuinely create confusion and mismanagement. Furthermore, the example of body builders serves to illustrate the inadequacy of the BMI as a diagnostic and management-determining criterion for obesity: it is unfit for clinical usage in the 21st century. Most frustratingly, the BMI does not provide an accurate and reliable clinical indicator of cardiovascular risk, which would provide a more logical scaffold than the BMI on which to stratify obesity-focused management options. Although commonly used for individual patients, it is interesting to note that when the BMI was first conceived by Ancel Keys in the 1970s, it was proposed for use in population-wide epidemiological settings rather than as a diagnostic tool in individual patients [15], and as such the BMI is not even a component of some composite risk scores for the estimation of cardiovascular risk such as the Framingham score or PROCAM. A re-definition of obesity would require international consensus and demand focused attention on the quiddity of obesity. Whilst ‘excessive adiposity’ would generally be regarded as an essential criterion, there are many questions that relate to age- and sex-dependent normal ranges, inter- and intra-individual differences in adiposity, and the development and implementation of clinical tools (including non-invasive biomarkers) for the accurate and reliable measurement of adiposity, including its distribution and inflammatory status. The process of such a re-definition of obesity would also likely broaden our minds beyond the role of adiposity per se in both the development of obesity but also as a sole treatment target and clinical outcome measure. Indeed, to properly re-define obesity we would need to take a more holistic metabolic perspective of adiposity in its wider pathophysiological context and consider important roles of other tissues and processes. Within this wider context, the skeletal muscle (SM) looms as a cynosure, but it is eclipsed by its surrounding adiposity. Unfortunately, the role of the SM in the development and management of obesity has been neglected, partly because of an over-emphasis on the BMI, but also due to a greater focus on the adipose tissue (AT). Recently, however, the SM has received attention in relation to clinical data from Glucagon-like Peptide 1 (GLP1)-related pharmacotherapies for T2D and obesity. It is therefore both timely and topical to review this topic. There is a close physical proximity and interplay between the SM and AT regarding their anatomy and physiology, a scenario that is ripe for bidirectional paracrine effects. Changes within the AT influence the SM and vice versa. In this concise review, we provide an overview of the key physiological roles of the SM and discuss the multitudinous interactions between the SM and AT in the wider context of metabolic health. We discuss the association of obesity with sarcopenia (a form of SM atrophy), the metabolic sequelae of sarcopenia (including the key role of the SM in determining insulin sensitivity), and the inherent difficulties of clinical assessment of SM mass and functioning in the context of obesity. We discuss the mechanisms that contribute to the loss of SM mass during body weight loss (including in the context of pharmacotherapies for obesity) and strategies to preserve SM mass and functioning, including the recent development of pharmacotherapies that can preserve and maintain SM mass and thereby mitigate against the loss of SM mass during weight loss, and their likely positioning in future treatment algorithms for obesity. Finally, we outline a future scenario in which body composition (the ‘Adipo–Muscle Ratio [AMR]’) rather than the BMI assumes a central position as a re-defined diagnostic criterion for obesity, and in which key clinical outcome measures focus on changes in body composition (including the AMR) rather than the percentage of body weight loss per se.
What the sources say
- Partly supportedcites [36] An, 2023, Adipose Tissue and Metabolic Health, Diabetes Metab. J. sourceExperimental — accuracy not yet measured
The Physiology sections describe adipose-derived factors with paracrine effects and report that adiponectin and BAT-derived myostatin act on skeletal muscle (pages unavailable in our copy). They do not establish close physical proximity between skeletal muscle and adipose tissue or bidirectional paracrine effects between them. (LLM, conf=0.85)
- Partly supportedcites [37] Rocha-Rodrigues, S., Matos, A., Afonso, J., Mendes-Ferreira, M., Abade, E., Teixeira, E., Silva, B., Murawska-Cialowicz, E., Oliveira, M.J., and Ribeiro, R. (2021). Skeletal Muscle-Adipose Tissue-Tumor Axis: Molecular Mechanisms Linking Exercise Training in Prostate Cancer. Int. J. Mol. Sci., 22. sourceExperimental — accuracy not yet measured
The Introduction describes crosstalk between skeletal muscle and white adipose tissue, supporting the claim of physiological interplay. It describes myokines and adipokines as acting in an endocrine-dependent manner, however, and does not establish close physical proximity or bidirectional paracrine signaling between these two tissues. The “Bidirectional Paracrine Signaling” subsection instead concerns adipocytes and cancer cells; page numbers are unavailable in our copy. (LLM, conf=0.88)
- Not checked yetcites [38] Shen, 2019, Myricanol modulates skeletal muscle-adipose tissue crosstalk to alleviate high-fat diet-induced obesity and insulin resistance, Br. J. Pharmacol. source
Checked before — its earlier verdict is held back until a new check runs.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Changes within the AT influence the SM and vice versa.”
§ Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management > 1. Introduction The global prevalence of obesity now exceeds 890 million, with overweight affecting around 2.5 billion adults [1]. The World Health Organisation (WHO) classifies obesity as a non-infectious global pandemic [1]. This positioning of obesity as a worldwide public health problem promotes renewed and redoubled efforts to develop and implement effective preventive, diagnostic, and management strategies. Obesity confers a substantial burden upon humanity, with impairments in quality of life and wellbeing that stem from its association with wide-reaching negative sequelae including impairments in psychosocial functioning [2] and work productivity [3]. Furthermore, obesity contributes towards a major component of global healthcare expenditure [4], originating from both the direct costs of obesity management, and the indirect costs associated with >50 obesity-related co-morbidities. Indeed, many chronic diseases that manifest within the modern-day clinical arena stem directly from weight gain and obesity or are at least pathophysiologically vulnerable to the metabolic and/or physical ramifications of obesity. Within this context, Type 2 Diabetes Mellitus (T2D) is notable, including a plethora of other obesity-related metabolic dysfunctional conditions such as dyslipidaemia, dysglycaemia, hypertension, Obstructive Sleep Apnoea (OSA), Polycystic Ovary Syndrome (PCOS), and Metabolic-Associated Fatty Liver Disease (MAFLD) [5]. Furthermore, obesity is associated with multiple malignancies that in turn contribute towards premature mortality [6,7]. Insulin resistance (IR, often associated with oxidative stress and chronic inflammatory status) is a key mediator between obesity and its adverse metabolic sequelae, and develops in the context of excessive adiposity, particularly visceral adiposity and ectopic fat deposition (epicardial, hepatic, and intramyocellular lipid [IMCL]) [8]. Obesity is a heterogeneous clinical entity with distinct subtypes based on underlying genetic architecture and clinical phenotypic biomarkers that include measures of insulin sensitivity, glycaemia, physical fitness, body composition, and cardiovascular risk [9]. One key challenge for the field of obesity is the relative lack of refinement concerning its definition. This has compounded societal misunderstanding of obesity and perhaps has also contributed towards a widespread stigmatisation and dispassionate perspective of obesity [10]. Such lack of diagnostic refinement has also stymied the development and implementation of more effective and targeted management guidelines for obesity from esteemed societies and has resulted in an unfortunate over-emphasis on ‘percentage body weight loss’ as a key outcome variable for both the clinical management of obesity and the assessment of novel therapies for obesity. The concept of ‘body weight divided by height squared’ as an indicator of body size was originally proposed by Quetelet and was widely adopted as the ‘Body Mass Index’ in the 1980s [11,12]. Since then, our definition of obesity has rested firmly on the BMI. To account for differences in overall cardiovascular risk between ethnic-specific groups based on the BMI, NICE provide ethnic-specific cut-offs for the BMI to define obesity. However, population-based data from a cohort in England demonstrate marked ethnic-specific variance in the risk of developing T2D based on the BMI [13]. To validate and confirm these insights, there is a requirement for further similar population-based studies on cohorts from different geographical locations and with controls for potential confounders such as socio-economic groups. Most guidelines on obesity management from esteemed societies refer solely to the BMI [14]. There are various problems with the BMI as a key solitary definition of obesity (and by implication nutritional status), not the least of which being that the BMI fails as a meaningful clinical entity at extremes of body habitus (in which there is either excessive or severely diminished muscularity) [12]. Furthermore, the BMI provides no indication of overall adiposity or body fat distribution (including the amount of visceral or ectopic fat). At one extreme, there are people with excessive muscularity (such as body builders) with lean mass exceeding 70% in some cases, in whom the BMI is elevated accordingly. Such a clinical scenario creates potential for confusion and mismanagement based on the imaginatively impoverished and unidimensional, but internationally accepted, BMI criteria for defining obesity and stratifying and prioritising its management approach. Whilst some readers may think that using the example of a body builder is meaningless as the absence of excessive adiposity is obvious clinically, there are plenty of other examples that are relatively common within the clinical arena where accurate assessment of the musculature is challenging, in which cases the application of the BMI can genuinely create confusion and mismanagement. Furthermore, the example of body builders serves to illustrate the inadequacy of the BMI as a diagnostic and management-determining criterion for obesity: it is unfit for clinical usage in the 21st century. Most frustratingly, the BMI does not provide an accurate and reliable clinical indicator of cardiovascular risk, which would provide a more logical scaffold than the BMI on which to stratify obesity-focused management options. Although commonly used for individual patients, it is interesting to note that when the BMI was first conceived by Ancel Keys in the 1970s, it was proposed for use in population-wide epidemiological settings rather than as a diagnostic tool in individual patients [15], and as such the BMI is not even a component of some composite risk scores for the estimation of cardiovascular risk such as the Framingham score or PROCAM. A re-definition of obesity would require international consensus and demand focused attention on the quiddity of obesity. Whilst ‘excessive adiposity’ would generally be regarded as an essential criterion, there are many questions that relate to age- and sex-dependent normal ranges, inter- and intra-individual differences in adiposity, and the development and implementation of clinical tools (including non-invasive biomarkers) for the accurate and reliable measurement of adiposity, including its distribution and inflammatory status. The process of such a re-definition of obesity would also likely broaden our minds beyond the role of adiposity per se in both the development of obesity but also as a sole treatment target and clinical outcome measure. Indeed, to properly re-define obesity we would need to take a more holistic metabolic perspective of adiposity in its wider pathophysiological context and consider important roles of other tissues and processes. Within this wider context, the skeletal muscle (SM) looms as a cynosure, but it is eclipsed by its surrounding adiposity. Unfortunately, the role of the SM in the development and management of obesity has been neglected, partly because of an over-emphasis on the BMI, but also due to a greater focus on the adipose tissue (AT). Recently, however, the SM has received attention in relation to clinical data from Glucagon-like Peptide 1 (GLP1)-related pharmacotherapies for T2D and obesity. It is therefore both timely and topical to review this topic. There is a close physical proximity and interplay between the SM and AT regarding their anatomy and physiology, a scenario that is ripe for bidirectional paracrine effects. Changes within the AT influence the SM and vice versa. In this concise review, we provide an overview of the key physiological roles of the SM and discuss the multitudinous interactions between the SM and AT in the wider context of metabolic health. We discuss the association of obesity with sarcopenia (a form of SM atrophy), the metabolic sequelae of sarcopenia (including the key role of the SM in determining insulin sensitivity), and the inherent difficulties of clinical assessment of SM mass and functioning in the context of obesity. We discuss the mechanisms that contribute to the loss of SM mass during body weight loss (including in the context of pharmacotherapies for obesity) and strategies to preserve SM mass and functioning, including the recent development of pharmacotherapies that can preserve and maintain SM mass and thereby mitigate against the loss of SM mass during weight loss, and their likely positioning in future treatment algorithms for obesity. Finally, we outline a future scenario in which body composition (the ‘Adipo–Muscle Ratio [AMR]’) rather than the BMI assumes a central position as a re-defined diagnostic criterion for obesity, and in which key clinical outcome measures focus on changes in body composition (including the AMR) rather than the percentage of body weight loss per se.
What the sources say
- Partly supportedcites [36] An, 2023, Adipose Tissue and Metabolic Health, Diabetes Metab. J. sourceExperimental — accuracy not yet measured
The Physiology section (page unavailable) says adiponectin enhances muscle glucose uptake, and the thermogenic-adipose-tissue Physiology section says brown adipose tissue produces myostatin that acts on skeletal muscle. These support an adipose-tissue-to-skeletal-muscle effect, but the passages found do not establish the claimed reverse effect of skeletal muscle changes on adipose tissue. (LLM, conf=0.85)
- Supportedcites [37] Rocha-Rodrigues, S., Matos, A., Afonso, J., Mendes-Ferreira, M., Abade, E., Teixeira, E., Silva, B., Murawska-Cialowicz, E., Oliveira, M.J., and Ribeiro, R. (2021). Skeletal Muscle-Adipose Tissue-Tumor Axis: Molecular Mechanisms Linking Exercise Training in Prostate Cancer. Int. J. Mol. Sci., 22. source
The Introduction describes communication between skeletal muscle and white adipose tissue through muscle-derived myokines and adipose-derived adipokines. Section 3.4 also describes effects in both directions: muscle-derived myokines can alter adipose tissue, while inflammatory adipokines and intramuscular adipose accumulation may affect skeletal-muscle insulin resistance. These passages support the broad claim of reciprocal influence. (LLM, conf=0.88)
- Supportedcites [38] Shen, 2019, Myricanol modulates skeletal muscle-adipose tissue crosstalk to alleviate high-fat diet-induced obesity and insulin resistance, Br. J. Pharmacol. source
The Abstract and Section 1 (INTRODUCTION) of our copy state that the crosstalk between adipose tissue and skeletal muscle is critical for insulin sensitivity and lipid/adiposity homeostasis, with the two tissues secreting adipokines and myokines 'to maintain metabolic homeostasis coordinately' — i.e. a bidirectional influence. Section 4 (DISCUSSION) reinforces both directions: skeletal-muscle irisin drives WAT browning while adipose tissue itself expresses Fndc5/secretes irisin and is a target of irisin ('not only a myokine but also an adipokine'), and dysregulated adipokines/myokines favour excess adiposity; the paper's own experimental design (Transwell co-culture of C2C12 myotubes with 3T3-L1 adipocytes, Section 2.4) is built on this reciprocal signalling. One mild caveat: the Discussion notes it 'needs to be elucidated whether the adipose tissue secretes feedback signals to close the myocyte–adipocyte circle,' but this does not contradict the general bidirectional-crosstalk statement the claim attributes. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As intimated earlier, there is a gradual reduction in SM mass with aging, which often becomes meaningful clinically from around the age of 50 years [17].”
§ Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management > 3. Results > 3.1. The Physiological Role of the SM and Its Decline with Aging
What the sources say
- Supportedcites [17] Merz, 2020, Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake, Compr. Physiol. source
The section “Links between aging and skeletal muscle insulin resistance” says that after ages 40–50, human skeletal muscle shows a gradual reduction in mass, accompanied by declining strength and function. This supports the claim’s approximate age and clinical significance, though the paper does not use the phrase “clinically meaningful.” (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Myokines (>600 peptides identified to date) influence the physiological function of the AT and other organs including bones and the brain [17].”
§ Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management > 3. Results > 3.2. The ‘Adipo–Muscle Axis’ and Relevance for Metabolic Health Having reviewed the essential role that the SM plays in the regulation of overall metabolic functioning and efficiency, and the progression of metabolic dysfunction with aging-associated diminishment of SM mass, in this section we consider the ‘Adipo–Muscle Axis’ (AMA): its physiological functioning and relevance for metabolic health (Figure 1). Although traditionally the physiological functioning and pathological potential of peripheral SM and AT have been considered as separate entities, the reality is that there is a close linkage between the SM and AT [36,37,38]. This close association manifests both anatomically, with the SM often surrounded and encased by the AT, and physiologically, through extensive crosstalk between the SM and AT that implicates bidirectional endocrine, autocrine, and paracrine effects. In this context, rather than taking the traditional perspective of considering each tissue type in isolation of the other, it is more meaningful to envision the SM and AT as a single functioning unit, at least from a metabolic perspective: an ‘AMA’. To understand the AMA better, it is useful to divide our discussion into molecules that originate from the SM (myokines) and from the AT (adipokines). This field is vast and goes beyond the scope of this concise review, and there are recent reviews that are more expansive [39]. Here, we simply provide a summary and discuss a few key myokines and adipokines to illustrate their roles in mediating crosstalk between the SM and AT.
What the sources say
- Supportedcites [17] Merz, 2020, Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake, Compr. Physiol. source
The “Mechanisms of myokine action” section says myokines mediate cross-talk with bone, brain, and adipose tissue, and that over 600 peptides produced and secreted by skeletal muscle have been identified. This supports the cited paraphrase. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Given its important role in glucose handling, the SM can be considered as a primary driver of whole-body IR [17].”
§ Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management > 3. Results > 3.1. The Physiological Role of the SM and Its Decline with Aging
What the sources say
- Supportedcites [17] Merz, 2020, Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake, Compr. Physiol. source
The section “Importance of skeletal muscle in insulin resistance” (page not available) explicitly calls skeletal muscle the primary driver of whole-body insulin resistance because it is the principal site of insulin-stimulated glucose uptake. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
53 more claims · 32 with their cited sources checked
Create a free account to see all 121 claims and to verify the 10 references still open.
- It may state two separate claims as one. 50
- Probably not a substantial claim. 26
Citations
Cites
A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Boström, E. A., Choi, J. H., Long, J. Z., et al. (2012) · Nature · doi:10.1038/nature10777 · Cited by 4,810 · cited 1×
“The impact of spexin on IR in human SM is unknown.”
Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr
Janssen, I., Heymsfield, S. B., Wang, Z., & Ross, R. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.89.1.81 · Cited by 3,087 · cited 3×
“Body height and weight accounted for around 50% of the variance in SM mass in both men and women, with linear and curvilinear relationships, respectively (the latter being due to the SM having less of a contribution towards weight gain with increasing body weight) [16].”
InfluentialLack of Exercise Is a Major Cause of Chronic Diseases
Booth, F. W., Roberts, C. K., & Laye, M. J. (2012) · Comprehensive Physiology · doi:10.1002/cphy.c110025 · Cited by 2,575 · cited 1×
“Unlike normal aging, the deleterious effects of secondary aging on the SM can be delayed through engagement in healthy lifestyle behaviours such as exercise and increased physical activity [17,35].”
Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
DeFronzo, R. A., & Tripathy, D. (2009) · Diabetes Care · doi:10.2337/dc09-s302 · Cited by 2,102 · cited 1×
“Furthermore, the SM accounts for >80% of glucose uptake in the post-prandial period following an oral glucose load, with linear increases in uptake over time [17,20].”
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 1×
“Indeed, with a weight loss of >10 Kg (and attendant loss of AT mass), there is recovery of β -cell function, and remission to a non-diabetic state in the context of T2D [22,23].”
Obesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis
Peeters, A., Barendregt, J. J., Willekens, F., Mackenbach, J. P., Mamun, A. A., Bonneux, L., & and for NEDCOM, T. N. E. A. D. C. O. M. R. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00008 · Cited by 1,479 · cited 1×
“Furthermore, obesity is associated with multiple malignancies that in turn contribute towards premature mortality [6,7].”
Visceral fat adipokine secretion is associated with systemic inflammation in obese humans
Fontana, L., Eagon, J. C., Trujillo, M. E., Scherer, P. E., & Klein, S. (2007) · Diabetes · doi:10.2337/db06-1656 · Cited by 1,417 · cited 1×
“Although the mechanisms that control SM mass during NEB remain incompletely understood, AA tracer techniques have provided some useful insights [85].”
Morton, R. W., Murphy, K. T., McKellar, S. R., Schoenfeld, B. J., Henselmans, M., Helms, E., Aragon, A. A., Devries, M. C., Banfield, L., Krieger, J. W., et al. (2018) · British Journal of Sports Medicine · doi:10.1136/bjsports-2017-097608 · Cited by 1,269 · cited 1×
“Bimagrumab is a monoclonal antibody against ActRII, which could mitigate against the decline in SM mass in the context of GLP1-induced NEB.”
Holland, W. L., Brozinick, J. T., Wang, L.-P., Hawkins, E. D., Sargent, K. M., Liu, Y., Narra, K., Hoehn, K. L., Knotts, T. A., Siesky, A., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.01.002 · Cited by 1,232 · cited 1×
“The inevitable loss of SM mass during NEB-induced body weight loss has important metabolic implications for dieting through the restriction of caloric intake.”
Muscle–Organ Crosstalk: The Emerging Roles of Myokines
Severinsen, M. C. K., & Pedersen, B. K. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa016 · Cited by 1,226 · cited 1×
“Although the majority of adipokines are implicated in promoting IR within the SM stemming from excessive AT mass, around half have also been demonstrated in vitro to have effects on myogenesis and/or SM hypertrophy [55].”
Cited by
Sepulveda, R. A. Y., Vasquez-Bonilla, A. A., Olivares, R., Olivares, P., Zavala-Crichton, J. P., Hinojosa-Torres, C., Muñoz-Strale, C., Giakoni-Ramírez, F., de Souza-Lima, J., Páez‐Herrera, J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-15264-6 · Cited by 15
“These results are unexpected considering that skeletal muscle plays a key role in health and metabolic efficiency 58 .”
Skeletal Muscle Mass Loss and Glucagon-Like Peptide-1 Receptor Agonists: Are Older Patients at Risk?
Kakkar, A. P., Ravussin, É., & LeJemtel, T. H. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03950 · Cited by 7
Longevity, Centenarians, and Lifestyle: Any ‘’Tips’’ to Live Longer?
Vetrani, C., Frias-Toral, E., Annunziata, G., Amatrudo, F., Mayol, D., Suárez, R., Verde, L., Negri, M., Piscitelli, P., Colao, A., et al. (2026) · Current Nutrition Reports · doi:10.1007/s13668-025-00724-2 · Cited by 4
“…increased risk of metabolic disorders and cardiovascular disease [33, 34] Thus, the solution to the BMI paradox is evident: translational geroscience should aim to maximize lean muscle mass and minimize visceral fat, regardless of BMI, in order to optimize the quality of mass over quantity [ 35].”
Stawiarska, A., Francik, R., Mikulec, A. T., Zborowski, M., Cisoń-Apanasewicz, U., Gajdosz, R., Zaczyk, I., Potok, H., Radom, A., Ogonowska, D., et al. (2025) · Metabolites · doi:10.3390/metabo15090591 · Cited by 1
“A decline in muscle mass impairs glucose metabolism, thereby increasing the risk of developing diabetes and metabolic syndrome [13].”
Optimizing Women’s Health Over the Lifespan: Why Body Composition, Bone Health and Fitness Matter
Bovard, R., Nadeau, A. M., Starchook-Moore, M. N., Dabrowski, D. S., Grob, C. H., & Anderson, P. J. (2025) · American Journal of Lifestyle Medicine · doi:10.1177/15598276251390867 · Cited by 2
Metadata
- Authors
- Barber, T. M., Kabisch, S., Pfeiffer, A. F. H., & Weickert, M. O.
- Affiliations
- University Hospital Coventry (GB)
- Helmholtz Munich (DE)
- Corresponding author
- Weickert, Martin O.
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2025-02-01
- Volume
- 15
- Issue
- 2
- Pages
- 85
- ISSN
- 2218-1989 (ISSN-L)
- PMC
- PMC11857510
- OpenAlex
- W4407141913
- Cited by
- 19
- References
- 130
- Citations by year
- 2026: 13 · 2025: 6
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Metabolites (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Warwick Research Archive Portal (University of Warwick) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
- Keywords
- obesity, skeletal muscle mass, myokines, adipokines, sarcopenic obesity, insulin resistance, dietary protein, resistance training, negative energy balance, obesity treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management. https://app.cochat.ai/papers/10.3390/metabo15020085
- The paper
- Barber, T. M., Kabisch, S., Pfeiffer, A. F. H., & Weickert, M. O. (2025). Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management. Metabolites. https://doi.org/10.3390/metabo15020085
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.